17 Innovators Highlight Investment to Solve Global Water Challenges
22.3.2023 18:15:00 EET | Business Wire | Press release
Seventeen organizations have joined forces to support the United Nations (UN) Water Action Agenda, pledging to invest $11 billion in water innovation over the next five years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230322005481/en/
Innovators highlight investment to solve global water challenges (Photo: Business Wire)
The collective commitment will be announced later today at an event organized by water technology company Xylem (NYSE: XYL) and the Kingdom of the Netherlands, convened during the UN 2023 Water Conference. The pledges will be included in the Water Action Agenda, a collection of all water-related commitments to accelerate progress on UN Sustainable Development Goal 6 targeting Water and Sanitation.
Executives from Xylem, Veolia, XPV, Hydraloop International, and Hansgrohe will be joined by several nonprofit organizations, to pledge their commitment to invest in innovative water solutions. The funds will be directed toward water-related research and development, start-up companies commercializing innovative approaches to water management, and the deployment of new water technologies. The organizations will also commit to ongoing engagement with development agencies, governments, and other stakeholders to facilitate more cross-sector action to solve water challenges.
“Most of humanity’s challenges today stem from our reliance on water, whether for human life or, on a larger scale, economic well-being and prosperity of society,” said Henk Ovink, Water Envoy of the Kingdom of the Netherlands. “We all need it, but in some places there is too much and in other places there isn’t enough. As significant water investors and users, the private sector has a pivotal role to play. The organizations pledging their commitment today are at the forefront of bringing new innovations to water use, treatment, and recycling. This type of collective action is essential to tackling major water challenges, and to creating a sustainable planet for future generations.”
The commitment from the private and philanthropic sectors to invest in water solutions supports the UN 2023 Water Conference’s call for clear pledges and actions, across all sectors, industries, and interests to achieve the UN Sustainable Development Goals.
“For those who can simply turn on a tap, water may not seem like a problem,” said Patrick Decker, CEO of Xylem. “But the UN 2023 Water Conference is a timely reminder that water challenges are intensifying around the world. The organizations making commitments today recognize these are challenges we can and must solve. Many of the essential technologies already exist, but as climate change progresses, we need more innovative solutions and accelerated implementation to increase the resilience and water-security of communities everywhere.”
The inclusion of the private sector in the UN 2023 Water Conference, the first event of its kind since 1977, has been welcomed as essential in developing an impactful Water Action Agenda. The conference brings together stakeholders from across governments, the private sector, non-governmental organizations, nonprofits, academic institutions, and the scientific community to advance transformative ideas that can solve global water challenges.
Organizations contributing to the pledge include Acciona, Autodesk, BlueTech, Burnt Island Ventures, The Coca-Cola Foundation, Evoqua, Grundfos, Hansgrohe, Hydraloop, Idexx, UGSI Solutions, Veolia, Water Foundry Ventures, Wavin, Westly Group, XPV and Xylem.
The event - Private Sector Investment Commitment to Water Innovation - will convene technology innovators, investors, government, civil society, and development agencies to consider the role of innovation in advancing the UN Sustainable Development Goals. Organized by Xylem and the Consulate General of the Kingdom of the Netherlands in New York, the event will be hosted in partnership with Bluetech Research, Burnt Island Ventures, Evoqua, the International Water Association, Mercy Corps, UNICEF, the Water Foundry, Veolia, the WateReuse Association, and the Water Research Foundation.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 17,000 diverse employees delivered revenue of $5.5 billion in 2022. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230322005481/en/
Contact information
Houston Spencer
+1 (914) 323-5723
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development7.7.2026 15:00:00 EEST | Press release
Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk of light-chain mispairing and providing a robust molecular foundation for subsequent BsADC development. By bringing together the complementary capabilities of Biocytogen and Whitehawk, the collaboration aims to identify BsADC candidates with differentiated targeting profiles and therapeutic potential. “W
UMA Unveils Its Vision for the Next Generation of Humanoid Robots7.7.2026 15:00:00 EEST | Press release
At Machina Summit, UMA, a Physical AI company, unveiled the design of its first humanoid robot and introduced Real-Time Learning, a learning architecture that enables robots to acquire new skills through demonstration instead of manual programming. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707215927/en/ The announcement comes as aging populations, industrial reshoring, and the energy transition place increasing pressure on labor markets across advanced economies. According to Korn Ferry, the global economy could face a shortage of 85 million workers by 2030, representing as much as $8.5 trillion in unrealized economic output. Against this backdrop, UMA is developing a new generation of intelligent robots built to assist people by taking on physically demanding, repetitive, or hazardous work. "Demographic, industrial, and environmental challenges all point to the same reality: societies need greater productive capacit
Bregal Milestone III Closes at its Increased Hard Cap of €915 Million7.7.2026 14:00:00 EEST | Press release
Bregal Milestone (“Milestone” or the “Firm”), a leading European software private equity firm, today announced the final close of its third fund, Bregal Milestone III (“Fund III” or the “Fund”), at its increased hard cap of €915 million. The Fund was oversubscribed and marks a significant broadening of the Firm’s global investor base. Completed in eight months from first close and achieved against a challenging fundraising environment, the result reflects the strength of Milestone’s AI-centric approach and demonstrable track record. Jan Bruennler, Philippe Lautenberg and Cyrus Shey, Co-Founders and Managing Partners at Bregal Milestone, commented: “Bregal Milestone III reflects strong conviction in our approach to investing in mission-critical European software, AI and cybersecurity businesses and helping them scale. We are thankful for the support and confidence shown by our limited partners, both longstanding and new, and remain focused on executing the strategy that has defined Mile
HTEC and Embotech Partner to Scale Deployment of Autonomous Driving Solutions for Industrial Logistics7.7.2026 13:39:00 EEST | Press release
HTEC, a global technology and AI engineering company headquartered in Silicon Valley, and Embotech, a global leader in safety-certified Level 4 autonomous driving solutions for industrial logistics, today announced a strategic partnership to scale deployment of Embotech's autonomous driving solutions across vehicle platforms, customer programmes and industrial sites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707870943/en/ HTEC, a global technology and AI engineering company headquartered in Silicon Valley, and Embotech, a global leader in safety-certified Level 4 autonomous driving solutions for industrial logistics, today announced a strategic partnership to scale deployment of Embotech's autonomous driving solutions across vehicle platforms, customer programmes and industrial sites. The partnership comes as Embotech’s proven autonomous driving solutions are being adopted across a growing number of vehicle platforms
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile7.7.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD) which confirm COMP360’s rapid onset and durable profile. The 26-week findings in nearly 600 patients build on previously reported results from the first Phase 3 trial, COMP005, which demonstrated rapid onset and durable response to at least 6 months, with a generally well-tolerated and safe profile in people living with TRD. The COMP360 Phase 3 program participants represent a highly chronic TRD population. In COMP006, participants had current depressive episodes lasting on average over three years and an average of more than six lifetime depressive episodes. Within the context of this severe population, 39% of participants in the 25 mg arm achieved a clinically m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom